FDA Makes Big Moves Amid Spread of Omicron Variant

With a rising number of COVID-19 cases due to the omicron variant, the FDA is making big moves. First, Pfizer's COVID-19 booster has been authorized for those ages 12 to 15. The agency also reduced the amount of time to wait between receiving a second vaccine dose and booster from six months to five. Finally, a third primary series dose of Pfizer's shot is approved for immunocompromised children five to 11 years old. Professor Peter Pitts joins Cheddar News to discuss.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.